Imuno
Imuno Therapeutics is a biotech company focused on developing the next generation of immunotherapies for hard-to-treat diseases, especially cancer. They leverage proprietary platforms like Imuno TACTICS™ to identify and target intracellular antigens, such as peptide-HLA complexes, with high specificity and safety. Their mission is to activate the immune system to destroy cancer cells and improve patient outcomes through precision immunotherapy.
Industries
Nr. of Employees
small (1-50)
Products
Program targeting p53 R175H (oncology)
A precision immunotherapy program directed at tumors presenting the p53 R175H peptide‑HLA complex; designed as a TCR‑mimic antibody in a T‑cell engager format to selectively target tumor cells.
Program targeting FLT3 D835Y (acute myeloid leukemia)
A precision antibody program against the FLT3 D835Y peptide‑HLA complex intended for AML treatment; described as a first‑in‑class program optimized for specificity.
Programs targeting novel and shared antigens for solid tumors
Discovery programs against undisclosed or novel peptide‑HLA targets intended for solid tumors, including indications described as checkpoint‑resistant.
Program targeting p53 R175H (oncology)
A precision immunotherapy program directed at tumors presenting the p53 R175H peptide‑HLA complex; designed as a TCR‑mimic antibody in a T‑cell engager format to selectively target tumor cells.
Program targeting FLT3 D835Y (acute myeloid leukemia)
A precision antibody program against the FLT3 D835Y peptide‑HLA complex intended for AML treatment; described as a first‑in‑class program optimized for specificity.
Programs targeting novel and shared antigens for solid tumors
Discovery programs against undisclosed or novel peptide‑HLA targets intended for solid tumors, including indications described as checkpoint‑resistant.
Services
Collaborative access to a discovery platform that identifies disease‑specific peptide‑HLA targets and produces candidate antibodies optimized for affinity and specificity.
Engineering and optimization of antibody modalities including T‑cell engager formats and preparation for IND enabling activities.
Collaborative access to a discovery platform that identifies disease‑specific peptide‑HLA targets and produces candidate antibodies optimized for affinity and specificity.
Engineering and optimization of antibody modalities including T‑cell engager formats and preparation for IND enabling activities.
Expertise Areas
- Precision immunotherapy
- Peptide‑HLA (pHLA/pMHC) target discovery
- TCR‑mimic antibody discovery
- Antibody engineering and T‑cell engager design
Key Technologies
- Peptide‑HLA (pHLA/pMHC) targeting
- TCR‑mimic antibody formats
- Antibody display technologies
- Machine learning for epitope/paratope prediction
News & Updates
Announcement of the launch of a new website for Imuno, highlighting their dedication to advancing immunotherapies in oncology and autoimmunity.
Exploration of the company's mission to activate the immune system to destroy cancer cells and their innovative approach using the Imuno TACTICS platform.
Discussion of developing therapies targeting the p53 protein, a key tumor suppressor, and their potential in cancer treatment.
An overview of how TCRmimic antibodies are being used to target cancer cells and improve immunotherapy outcomes.
Announcement of the launch of a new website for Imuno, highlighting their dedication to advancing immunotherapies in oncology and autoimmunity.
Exploration of the company's mission to activate the immune system to destroy cancer cells and their innovative approach using the Imuno TACTICS platform.
Discussion of developing therapies targeting the p53 protein, a key tumor suppressor, and their potential in cancer treatment.
An overview of how TCRmimic antibodies are being used to target cancer cells and improve immunotherapy outcomes.